BioSpace News Archive

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

Rezolute, Inc., a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, announced the initiation of sunRIZE, a pivotal Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism.

Cadenza Bio, Inc., a privately-held biotechnology company focused on developing novel small molecule compounds for demyelinating and inflammatory diseases, has announced the initial closing of an oversubscribed $2.44M Series Seed financing.

Applied DNA Sciences, Inc. and Kudo Biotechnology announced their entry into a joint development agreement to integrate Applied DNA’s Linea™ IVT platform into Kudo Bio’s commercial mRNA manufacturing workflows.

BioStem Technologies Inc. announced that the Center for Medicare Services has established national pricing for its product, AmnioWrap2™, in all Medicare Administrative Contractors regions.

Velia Therapeutics, a biotechnology company focused on the discovery and development of a new generation of protein-based therapeutics that address the underlying causes of difficult-to-treat diseases, today announced that Michael York has joined the organization as chief business officer.

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the company’s Phase 1 trial of MZE829 in healthy volunteers.

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today announced the publication of a peer-reviewed article describing brain target engagement by CNM-Au8®, the company’s lead drug candidate.

Neogen Corporation announced that it is collaborating with the Cat Fanciers’ Association, a leading authority in feline advocacy.

Haystack Oncology, a Quest Diagnostics company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncology’s industry-leading personalized MRD technology to help evaluate therapeutic response and provide molecular insights for a Rutgers Cancer Institute clinical trial examining early-stage triple-negative breast cancer patients undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.